Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle

BACKGROUND: Modulating myosin function is a novel therapeutic approach in patients with cardiomyopathy. Danicamtiv is a novel myosin activator with promising preclinical data that is currently in clinical trials. While it is known that danicamtiv increases force and cardiomyocyte contractility witho...

Descripción completa

Detalles Bibliográficos
Autores principales: Kooiker, Kristina B., Mohran, Saffie, Turner, Kyrah L., Ma, Weikang, Martinson, Amy, Flint, Galina, Qi, Lin, Gao, Chengqian, Zheng, Yahan, McMillen, Timothy S., Mandrycky, Christian, Mahoney-Schaefer, Max, Freeman, Jeremy C., Costales Arenas, Elijah Gabriela, Tu, An-Yu, Irving, Thomas C., Geeves, Michael A., Tanner, Bertrand C.W., Regnier, Michael, Davis, Jennifer, Moussavi-Harami, Farid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434831/
https://www.ncbi.nlm.nih.gov/pubmed/37470183
http://dx.doi.org/10.1161/CIRCRESAHA.123.322629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434831/
https://www.ncbi.nlm.nih.gov/pubmed/37470183
http://dx.doi.org/10.1161/CIRCRESAHA.123.322629

Ejemplares similares